“P-selectin,” “adhesion,” and “in vivo” appeared earlier (in 2018 or earlier), while “endothelial dysfunction,” “complications,” and “plasminogen activator inhibitor-1 (PAI-1)” appeared later, around 2022, indicating emerging research hotspots. Here, SERPINE1 is linked to endothelial dysfunction.